Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

2022; Massachusetts Medical Society; Volume: 387; Issue: 25 Linguagem: Inglês

10.1056/nejmoa2205982

ISSN

1533-4406

Autores

Evan S. Dellon, Marc E. Rothenberg, Margaret H. Collins, Ikuo Hirano, Mirna Chehade, Albert J. Bredenoord, Alfredo J. Lucendo, Jonathan M. Spergel, Seema S. Aceves, Xian Sun, Matthew P. Kosloski, Mohamed Kamal, Jennifer D. Hamilton, Bethany Beazley, Eilish McCann, Kiran Patel, Leda Mannent, Elizabeth Laws, Bolanle Akinlade, Nikhil Amin, Wei Keat Lim, Matthew F. Wipperman, Marcella Ruddy, Naimish Patel, David R. Weinreich, George D. Yancopoulos, Brad Shumel, Jennifer Maloney, Angeliki Giannelou, Arsalan Shabbir,

Tópico(s)

Eosinophilic Disorders and Syndromes

Resumo

Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis.

Referência(s)